Drug Profile
IGV 001
Alternative Names: IGF-1R antisense therapy; IGF-1R/AS ODN; IGV-001; Insulin growth factor receptor type 1 antisense therapy; Type 1 insulin growth factor receptor antisense therapyLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Thomas Jefferson University
- Developer Imvax; Thomas Jefferson University
- Class Antineoplastics; Antisense oligonucleotides; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Preclinical Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Glioblastoma(First-line therapy) in USA (SC, Implant)
- 08 Aug 2023 Pharmacodynamics data from a preclinical study in Glioblastoma released by Imvax
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Glioblastoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)